- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04763226
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
A Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986308 in Healthy Participants
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Local Institution - 0001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Must be in good health, as determined by no clinically significant deviations from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations
- Must have a body mass index (BMI) of 18.0 kg/m^2 to 32.0 kg/m^2, inclusive, at screening. BMI = weight (kg)/height (m)^2
- Must have normal renal function at screening (and study admission) as evidenced by an estimated glomerular filtration rate (eGFR) ≥ 80 mL/min/1.73 m^2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula
Exclusion Criteria:
- Any significant acute or chronic medical illness
- Presence or need for urinary catheterization, urinary tract abnormality, or disorder interfering with urination
- History of tinnitus or hearing impairment, including deafness
- History or risks factors for Torsade de Pointes and Long QT syndrome (such as electrolyte imbalances, etc)
- History of, or active, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
- Consumption of caffeine or xanthine-containing food or beverages within 72 hours prior to study treatment administration
- Use of any prescription drugs or over-the-counter (OTC) acid controllers within 4 weeks prior to study treatment administration except those medications cleared by the Medical Monitor
- Use of any other drugs, including OTC medications within 1 week and herbal preparations, within 2 weeks prior to study treatment administration except those medications cleared by the Medical Monitor
- Use of diuretics (loop diuretics, thiazide diuretics, potassium-sparing diuretics [spironolactone, amiloride]), oral calcium, potassium or magnesium supplements (including multi-vitamins) or use of non-steroidal anti-inflammatory drugs within 72 hours of the first study treatment
- Use of concomitant medications that are strong inhibitors or inducers of cytochrome CYP3A4 or OATP administered within 2 weeks prior to study treatment administration and throughout the study
- Consumption of any nutrients known to modulate cytochrome P450 (CYP) enzymes activity (eg, grapefruit, or grapefruit juice,pomelo juice, star fruit, or Seville [blood] orange products) within 14 days prior to first administration of study treatment
- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population of healthy volunteers
- History of allergy to furosemide, sulfonamides, other loop diuretics (furosemide cohort only), BMS-986308 or related compounds, components of the suspension or solution, including hydroxypropylmethylcellulose
Other protocol-defined inclusion/exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A Furosemide
|
Specified dose on specified days
|
Experimental: Part B (SAD)
Single Ascending Dose (SAD)
|
Specified dose on specified days
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events (AEs)
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of serious adverse events (SAEs)
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of death
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of adverse events (AEs) leading to discontinuation
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in clinical laboratory results: Hematology tests
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in vital signs: Respiratory rate
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in vital signs: Supine blood pressure
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in vital signs: Heart rate
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in vital signs: Orthostatic hypotension measurements performed as per clinical research unit's standard operating procedure
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval
Time Frame: Up to 19 days
|
Part B PR interval is the time from the onset of the P wave to the start of the QRS complex |
Up to 19 days
|
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS
Time Frame: Up to 19 days
|
Part B QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization |
Up to 19 days
|
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval
Time Frame: Up to 19 days
|
Part B The QT interval is the time from the start of the Q wave to the end of the T wave |
Up to 19 days
|
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF
Time Frame: Up to 19 days
|
Part B QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave |
Up to 19 days
|
Incidence of clinically significant changes in cardiac telemetry
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Incidence of clinically significant changes in physical examination findings
Time Frame: Up to 19 days
|
Part B
|
Up to 19 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events (AEs)
Time Frame: Up to 14 days
|
Part A
|
Up to 14 days
|
Incidence of serious adverse events (SAEs)
Time Frame: Up to 72 days
|
Part A
|
Up to 72 days
|
Incidence of death
Time Frame: Up to 72 days
|
Part A
|
Up to 72 days
|
Incidence of adverse events (AEs) leading to discontinuation
Time Frame: Up to 72 days
|
Part A
|
Up to 72 days
|
Incidence of clinically significant changes in vital signs: Respiratory rate
Time Frame: Up to 14 days
|
Part A
|
Up to 14 days
|
Incidence of clinically significant changes in vital signs: Supine blood pressure
Time Frame: Up to 14 days
|
Part A
|
Up to 14 days
|
Incidence of clinically significant changes in vital signs: Heart rate
Time Frame: Up to 14 days
|
Part A
|
Up to 14 days
|
Incidence of clinically significant changes in vital signs: Orthostatic hypotension measurements performed as per clinical research unit's standard operating procedure
Time Frame: Up to 3 days
|
Part A
|
Up to 3 days
|
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval
Time Frame: Up to 14 days
|
Part A PR interval is the time from the onset of the P wave to the start of the QRS complex |
Up to 14 days
|
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS
Time Frame: Up to 14 days
|
Part A QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization |
Up to 14 days
|
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval
Time Frame: Up to 14 days
|
Part A The QT interval is the time from the start of the Q wave to the end of the T wave |
Up to 14 days
|
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF
Time Frame: Up to 14 days
|
Part A QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave |
Up to 14 days
|
Incidence of clinically significant changes in cardiac telemetry
Time Frame: Up to 3 days
|
Part A
|
Up to 3 days
|
Incidence of clinically significant changes in physical examination findings
Time Frame: Up to 14 days
|
Part A
|
Up to 14 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CV021-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneNot yet recruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbRecruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruitingHealthy ParticipantsCanada
-
Novo Nordisk A/SRecruiting
Clinical Trials on Furosemide
-
NYU Langone HealthWithdrawnPremature Birth | Premature InfantUnited States
-
Johns Hopkins UniversityscPharmaceuticals, Inc.Completed
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart FailureUnited States, Canada
-
Jan Kochanowski UniversityRecruiting
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedBronchopulmonary DysplasiaUnited States
-
Chiang Mai UniversityRecruiting
-
Stadtspital ZürichOspedale Regionale di LuganoRecruitingAcute Heart Failure | Diuretic ResistanceSwitzerland
-
Puerta de Hierro University HospitalInstituto de Salud Carlos III; Spanish Society of CardiologyCompleted